Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane

NCT ID: NCT01199471

Last Updated: 2012-01-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-09-30

Study Completion Date

2010-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry is primarily aiming to demonstrate the correlation between good practices of anesthesiologists and patient related outcomes including decreased overall anesthesia cost. The investigators would also like to demonstrate how the training background, and experience in inhalational anesthesia of the anesthesiologist influence their daily practice. At the end of the registry, the investigators would be able to demonstrate the influence of different practice pattern on patient related outcomes between the sites at which anesthesiologists follow modern anesthesiology practice based on their training/experience background and at which anesthesiologists do not follow same type of practice due to lack of their inhalational anesthesia training/experience.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anesthesia, General

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chinese Patients Requiring Surgery with Anesthesia

Chinese patients 18 to 70 years of age, meeting the American Society of Anesthesiologists (ASA) Physical Status Class 1 (normal healthy), Class 2 (mild systemic disease), or Class 3 (severe systemic disease), who underwent surgery requiring general anesthesia (sevoflurane) administered per local Prescribing Information and endotracheal intubation or laryngeal mask airway (LMA).

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ASA (American Society of Anesthesiologists) physical status (a requirement of the patient's physical status): I to III
2. Age from 18 to 70 years
3. Surgery requiring general anesthesia with endotracheal intubation or laryngeal mask airway.

Exclusion Criteria

1. History of significant cardiovascular, pulmonary, renal, hepatic or central nervous system disease or muscle disease.
2. Hypersensitivity or unusual response to any halogenated anesthetics.
3. Personal or familial history of malignant hyperthermia.
4. Female patients either pregnant or breast feeding.
5. General anesthesia is administered with total intravenous anesthesia (TIVA) of propofol.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rundo-Cronova International Pharmaceuticals Research & Development Co., Ltd.

UNKNOWN

Sponsor Role collaborator

Abbott

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yue Kang, MD

Role: STUDY_DIRECTOR

Abbott

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Site Reference ID/Investigator# 43073

Guangzhou, Guangdong, China

Site Status

Site Reference ID/Investigator# 43072

Guangzhou, Guangdong, China

Site Status

Site Reference ID/Investigator# 46407

Guangzhou, Guangdong, China

Site Status

Site Reference ID/Investigator# 43076

Guangzhou, Guangdong, China

Site Status

Site Reference ID/Investigator# 43077

Guangzhou, Guangdong, China

Site Status

Site Reference ID/Investigator# 43066

Harbin, Heilongjiang, China

Site Status

Site Reference ID/Investigator# 43068

Harbin, Heilongjiang, China

Site Status

Site Reference ID/Investigator# 43071

Wuhan, Hubei, China

Site Status

Site Reference ID/Investigator# 43070

Wuhan, Hubei, China

Site Status

Site Reference ID/Investigator# 43065

Chengdu, Sichuan, China

Site Status

Site Reference ID/Investigator# 43064

Chengdu, Sichuan, China

Site Status

Site Reference ID/Investigator# 43056

Beijing, , China

Site Status

Site Reference ID/Investigator# 43060

Beijing, , China

Site Status

Site Reference ID/Investigator# 46406

Beijing, , China

Site Status

Site Reference ID/Investigator# 43058

Beijing, , China

Site Status

Site Reference ID/Investigator# 44382

Beijing, , China

Site Status

Site Reference ID/Investigator# 43059

Beijing, , China

Site Status

Site Reference ID/Investigator# 43062

Beijing, , China

Site Status

Site Reference ID/Investigator# 43063

Beijing, , China

Site Status

Site Reference ID/Investigator# 43061

Beijing, , China

Site Status

Site Reference ID/Investigator# 43057

Beining, , China

Site Status

Site Reference ID/Investigator# 44384

Daqing, , China

Site Status

Site Reference ID/Investigator# 44383

Guangzhou, , China

Site Status

Site Reference ID/Investigator# 43074

Guangzhou, , China

Site Status

Site Reference ID/Investigator# 43067

Harbin, , China

Site Status

Site Reference ID/Investigator# 43051

Jiangsu, , China

Site Status

Site Reference ID/Investigator# 43015

Shanghai, , China

Site Status

Site Reference ID/Investigator# 43017

Shanghai, , China

Site Status

Site Reference ID/Investigator# 41554

Shanghai, , China

Site Status

Site Reference ID/Investigator# 46405

Shanghai, , China

Site Status

Site Reference ID/Investigator# 43012

Shanghai, , China

Site Status

Site Reference ID/Investigator# 43014

Shanghai, , China

Site Status

Site Reference ID/Investigator# 43011

Shanghai, , China

Site Status

Site Reference ID/Investigator# 43018

Shanghai, , China

Site Status

Site Reference ID/Investigator# 46404

Shanghai, , China

Site Status

Site Reference ID/Investigator# 43069

Wuhan, Hubei, , China

Site Status

Site Reference ID/Investigator# 43052

Zhejiang, , China

Site Status

Site Reference ID/Investigator# 43053

Zhejiang, , China

Site Status

Site Reference ID/Investigator# 43054

Zhejiang, , China

Site Status

Site Reference ID/Investigator# 43055

Zhejiang, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P12-563

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.